by GlyTherix | Jan 13, 2025 | Glypican-1, GlyTherix
On 13 January 2025, GlyTherix Ltd and Eckert & Ziegler announced the expansion of their existing Lutetium-177-based collaboration with a global supply agreement for Actinium-225. Eckert & Ziegler will provide high-quality Ac-225 to support GlyTherix’s clinical...
by GlyTherix | Dec 10, 2024 | Glypican-1, GlyTherix, Miltuximab
GlyTherix and Nusano, a physics company transforming the production of radioisotopes, today announced a supply agreement for non-carrier-added lutetium-177 (Lu-177). The agreement also provides GlyTherix access to Nusano’s future actinium-225 (Ac-225) production,...
by GlyTherix | May 24, 2023 | Glypican-1
Learn more about our Glypican-1 (GPC-1) antibody as a targeted therapy for delivering a radioactive payload to cancer cells. The evidence for GPC-1 being a key target in cancer therapy continues to expand rapidly. This includes recent publications with our...
by GlyTherix | Sep 8, 2022 | Glypican-1, Miltuximab
GlyTherix Ltd today announces that it has been jointly awarded a $4.8 million Australian Research Council (ARC) grant to establish a new Industrial Transformation Research Program (ITRP) Hub as part of a consortium of applicants led by The University of Queensland....
by GlyTherix | Jul 16, 2020 | Glypican-1, GlyTherix
16th July 2020: Sydney • Project boasts a dream team of world class partners across antibody manufacturing and clinical trials • Grant will support development of national capability in manufacture and distribution of radioimmuno-oncology drugs • GlyTherix’s...
by GlyTherix | May 19, 2020 | Glypican-1, GlyTherix, Miltuximab
Tuesday 19th May 2020: Sydney GlyTherix Ltd (GlyTherix) is pleased to report publication of four new peer reviewed papers covering both basic science as well as pre-clinical studies around our proprietary novel target, Glypican-1 and our lead antibody to this target,...
